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Objectives This study evaluated the association between
environmental factors and genetic variations in enzymes
that metabolize antituberculosis (anti-TB) drugs [arylamine
N-acetyltransferase 2, cytochrome P450 2E1 (CYP2E1),
glutathione S-transferase theta 1 (GSTT1), and glutathione
S-transferase mu 1] with antituberculosis drug-induced
hepatotoxicity (ATDH). We also investigated the potential
gene–gene and gene–environment interactions as well as
their association with ATDH development in a population of
hospitalized TB patients from Buenos Aires.
Patients and methods We investigated 364 TB patients
who received anti-TB drugs. Physicians collected
demographic and clinical data to identify environmental risk
factors for ATDH development. Polymorphisms were
detected using gene sequencing, PCR, and PCR-restriction
fragment length polymorphisms. A binary logistic
regression analysis was carried out to compare the results
of TB patients with and without the development of
hepatotoxicity. The multifactor dimensionality reduction
method was used to examine genetic and environmental
interactions in association with ATDH.
Results This study suggests that the slow acetylator profile
[odds ratio (OR): 3.02; 95% confidence interval (CI):
1.82–5.00; P< 0.001], genotypes carrying the c2 variant (OR:
2.16; 95% CI: 1.33–3.51; P= 0.002) or the A4 variant of
CYP2E1 (OR: 2.13; 95% CI: 1.06–4.29; P= 0.050), and female
sex (OR: 1.94; 95% CI: 1.20–3.14; P= 0.006) were
independent predictor variables for ATDH. Patients carrying
the slow acetylator profile and the c2 variant showed an
increased risk (OR: 7.068; 95% CI: 3.34–14.95; P< 0.001).
We also identified a synergic interaction (epistasis) between
GSTT1 and CYP2E1 associated with an increased risk for
ATDH. A meaningful gene–environment interaction was
associated with an increased risk of ATDH [testing balance
accuracy= 0.675 (P= 0.001) and cross-validation
consistency= 10/10].
Conclusion ATDH is a severe and prevalent adverse drug
reaction and leads to drug discontinuation in 11% of TB
patients. Our study created a prediction model that properly
classified the 67.5% of TB patients in their risk of developing
ATDH. The considerable number of TB patients in our
country supports the use of pharmacogenetic testing and a
comprehensive clinical history to identify patients with a
high risk of suffering hepatotoxicity. Pharmacogenetics and
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Introduction
Tuberculosis (TB) is the second leading cause of death
from an infectious disease worldwide after HIV and it
remains a major worldwide health problem, with an
estimated 9.0 million new cases and 1.5 million deaths in
2013 [1,2]. Latent tuberculosis infection (LTBI) affects
approximately one-third of the world’s population.
Approximately 10% of individuals with LTBI develop
active TB disease in their lifetime, with most individuals
developing it within 5 years after the initial infection [3].
LTBI is frequently treated with isoniazid (INH) mono-
therapy because of its widely known effectiveness
against Mycobacterium tuberculosis [4]. Treatment of acute
TB involves a multidrug therapy with first-line drugs
[INH, rifampicin (RMP), ethambutol, and pyrazinamide
(PZA)] for the first 2 months. Patients continue treatment
with a sterilization phase of 4–6 months with INH and
RMP [5].
Drug-induced liver injury (DILI) is becoming a sig-
nificant public health issue because of its potential
impact on patients, new drug development, and
increased health costs [6]. Antituberculosis drug-induced
hepatotoxicity (ATDH) is a severe, potentially fatal, and
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prevalent adverse drug reaction, and it leads to drug
discontinuation in 11% of TB patients treated with a
PZA, RMP, and INH regimen [7]. Several surveys found
that INH was primarily responsible for liver injury [8–10].
A recently published meta-analysis suggested that INH
monotherapy led to higher rates of hepatotoxicity than
RMP monotherapy [11]. Sarma et al. [12] reported that
combined INH and RMP treatment increased the risk of
hepatotoxicity through the induction of amidase enzyme,
which increased concentrations of a toxic metabolite of
INH, hydrazine (Hz).
INH is metabolized in the liver and it is primarily
excreted in the urine. INH is acetylated by
N-acetyltransferase 2 (NAT2) in the liver to form acetyl
isoniazid and hydrolyzed by amidase to acetyl hydrazine,
which may be re-acetylated by NAT2 to diacetyl hydra-
zine (nontoxic). However, acetyl hydrazine may also be
oxidized to hepatotoxic intermediates by cytochrome
P450 2E1 (CYP2E1) [13]. An alternative pathway directly
hydrolyzes INH to form Hz [13]. RMP is a potent
inducer of CYP2E1 activity that also reduces NAT2
activity [14,15]. The formation of reactive metabolites
may lead to oxidative stress, mitochondrial damage, and
initiation of prodeath signaling pathways [16]. The
detoxification of toxic INH metabolites involves con-
jugation reactions by glutathione S-transferases (GSTs),
which is a family of phase II enzymes that play an
important protective role as intracellular free radical sca-
vengers [17,18].
Some studies of the pharmacogenetics of TB found an
association between genetic variations in these enzymes
and ATDH development [10,19–21]. The NAT2 gene
was studied widely, and several surveys found an asso-
ciation between the slow acetylator phenotype and
ATDH development [10,19,20,22]. The single nucleotide
polymorphism (SNP) C-1053T in the CYP2E1 gene, also
called c1/c2 or the RsaI variant, is one of the most studied
genetic variants that is also associated with ATDH sus-
ceptibility [21,23]. Deficiency in GST activity, caused by
glutathione S-transferase mu 1 (GSTM1) and glutathione
S-transferase theta 1 (GSTT1) null mutations, was asso-
ciated with idiosyncratic DILI from a large variety of
drugs [24] and ATDH development [18,25].
TB is a re-emerging infectious disease with a high
level of hepatotoxicity (25.6%) in hospitalized TB
patients in Argentina [19]. Therefore, the present
survey investigated the environmental factors and
pharmacogenetic variation involved in INH metabo-
lism and evaluated their association with ATDH
independently and/or through complex interactions
between them in a sample of hospitalized TB patients
in Buenos Aires.
Patients and methods
Patients
We enrolled a total of 364 patients who were treated for
active TB between 2009 and 2015 at the Hospital of
Infectious Disease ‘Dr F. J. Muñiz’ (Buenos Aires,
Argentina). The ethics committee of the Hospital
reviewed and approved the study protocol, which was
performed according to the principles of the Declaration
of Helsinki. All patients provided written informed con-
sent to participate in the study. Pulmonologists carefully
selected the TB patients, obtained written informed
consent, and performed blood extractions and clinical
data collection. Nineteen of the 364 patients had
incomplete clinical data and were excluded. The inclu-
sion and exclusion criteria have been described pre-
viously [19].
The following data were collected from patients: sex, age,
nationality, BMI (BMI< 16 kg/m2 was considered severely
underweight and indicative of malnourishment), smoking
habits, alcohol abuse (>60 g/day in men and > 40 g/day in
women), any associated diseases (diabetes, HIV infection,
any immunosuppressive treatments, Chagas disease, and/
or intestinal parasites), history of illegal drug abuse, and
ATDH development. Hepatotoxicity was defined as ala-
nine aminotransferase levels at least three times the upper
limit of normal with hepatitis symptoms (nausea, vomiting,
abdominal pain, and/or hyporexia) and/or jaundice reported
or alanine aminotransferase level at least five times the
upper limit of normal in the absence of symptoms [19].
All patients had normal liver tests before they received
anti-TB drugs, which allowed us to differentiate healthy
livers from acute or chronic alcoholic liver disease.
All patients were monitored clinically. Symptomatic
patients were monitored using weekly biochemical
assessments. Asymptomatic patients were monitored
using biochemical assessments every 15 days.
DNA samples
Whole-blood samples from TB patients were collected in
tubes containing ethylenediaminetetraacetic acid. Genomic
DNA was extracted using an automated platform using the
QIAamp DNAMini Kit (Qiagen, Valencia, California, USA)
according to the manufacturer’s instructions. The extracted
genomic DNA was analyzed using 2% agarose gel
electrophoresis.
Genotyping
DNA samples from each patient were analyzed for poly-
morphisms in CYP2E1, NAT2, GSTM1, and GSTT1 genes.
Seven of the most common NAT2 polymorphisms
[rs1801279 (G191A), rs1041983 (C282T), rs1801280
(T341C), rs1799929 (C481T), rs1799930 (G590A), rs1208
(A803G), and rs1799931 (G857A)] were analyzed. The
entire open reading frame of the NAT2 gene was ampli-
fied using PCR, and the product was purified and
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sequenced on both strands to genotype polymorphisms.
NAT2 polymorphism genotyping has been described
previously [26]. The NAT2PRED web server was used
to infer the acetylator phenotype (rapid, intermediate,
and slow acetylators) [27].
The variable-number tandem repeat (VNTR) poly-
morphism located in the 5′-untransleted region (− 2173
and − 1946) of the CYP2E1 gene was screened using
PCR-restriction fragment length polymorphisms (pri-
mers: F-5′-AAGCCTGAAGAACACCCTGC-3′ and R-
5′-CTGTGGTCTGAGTCCTCTGG-3′). PCR amplifi-
cation was performed as described previously, with
omission of the final extension step [28]. Four different
VNTR alleles were described: A1 (five repeats), A2 (six
repeats; also named 1C), A3 (six repeats), and A4 (eight
repeats; also named 1D) [29]. PCR products were
digested with the restriction enzyme NlaIV as described
by Catanzaro et al. [30] Genotyping for the CYP2E1 SNP
C-1053T, also named the c1/c2 polymorphism and/or the
RsaI variant (rs2031920), was performed using PCR-
restriction fragment length polymorphisms. A 413-bp
fragment was treated with an RsaI restriction enzyme.
Loss of the RsaI restriction site indicates the presence of
the c2 allele. PCR and digestion conditions have been
described previously [19].
The GSTM1 null polymorphism was performed using
multiplex PCR (primers: F-5′-GAACTCCCTGAAAAG
CTAAAGC-3′ and R-5′-GACAGGGTTTCATCATGT
TGG- 3′) under the following conditions: (a) an initial
denaturation at 95°C for 5 min; (b) 37 thermal cycles of
1 min at 95°C to denature the DNA, 45 s at 55°C to
anneal the primers, and 45 s at 72°C for DNA poly-
merization; and (c) a 10-min incubation at 72°C to ensure
complete product extension. A 345-bp band (Factor II
gene) and a 219-bp band (GSTM1 gene) were identified
in patients who were GSTM1 wild type. The latter band
was missing in individuals who were GSTM1 null. The
GSTT1 null polymorphism was performed using multi-
plex PCR (primers: F-5′- TTCCTTACTGGTCCT
CACATCTC-3′ and R-5′- TCACCGGATCATGGCC
AGCA-3′) under the following conditions: (a) an initial
denaturation at 95°C for 5 min; (b) 38 thermal cycles of
50 s at 95°C to denature the DNA, 40 s at 58°C to anneal
the primers, and 45 s at 72°C for DNA polymerization;
and (c) a 10-min incubation at 72°C to ensure complete
product extension. Factor II gene was used as an internal
control (primers: F-5′-TCTAGAAACCAGTTGCCTG
GC-3′ and R-5′-ATAGCACTGGGAGCATTGAAGC-3′).
A 345-bp band (Factor II gene) and a 459-bp band
(GSTT1 gene) were identified in wild-type GSTT1, and a
single 345-bp band was observed in the GSTT1 null
genotype.
All PCR products and their corresponding digested
fragments were analyzed using 2% agarose gel
electrophoresis with SYBR Safe staining (Invitrogen,
Paisley, UK).
Statistical analysis
The SPSS (version 23.0 for Windows; IBM SPSS Inc.,
Chicago, Illinois, USA) was used for statistical analyses.
The data were not normally distributed, and results are
presented as medians and percentiles (25 and 75) or
percentages for categorical variables. Nonparametric tests
(independent-samples median test) were used to com-
pare the quantitative data and the χ2-test was used to
compare proportions.
To predict ATDH, we used the χ2 outcomes and those
independent variables with a significance P-value less
than 0.1 were selected to a further binary logistic
regression. A binary logistic regression (method: forward
conditional) analysis was carried out to examine the
association between ATDH and the independent vari-
ables selected. The odds ratio (OR) with a 95% con-
fidence interval (CI) was estimated to assess the strength
of this association. Inheritance models (recessive, domi-
nant, additive, etc.) were established using a likelihood
test ratio. We used the Hardy–Weinberg (HW) test to
evaluate the heredity equilibrium.
Testing for genetic and environmental interactions in
association with ATDH was performed using the multi-
factor dimensionality reduction (MDR) method [31],
version beta 3.0.2. All two-way to five-way models were
evaluated. Balanced accuracy in the context of 10-fold
cross-validation was used to assess model quality. An
overall best model was selected that had the maximum
accuracy in the testing data. Cross-validation consistency
(CVC) was recorded. Statistical significance was deter-
mined by comparing the average CVC from the observed
data with the distribution of average consistencies under
the null hypothesis of no associations derived empirically
from 1000 permutations. The entropy decomposition
provides distinguishable additive and nonadditive
effects, and thus identifies the size and direction (synergy
or redundancy) of epistasis among attributes. A positive
information gain (positive entropy) indicates a synergistic
or a nonadditive effect, whereas a negative information
gain value (negative entropy) indicates redundancy or
correlation. Interaction dendrograms were used to
visualize interaction and hierarchical clustering was used
to construct a dendrogram that places strongly interacting
attributes close together at the leaves of the tree.
A P-value less than 0.05 was considered statistically
significant.
Results
This study included 345 hospitalized TB patients and 96
patients developed ATDH (cases). The median age of
the total study population was 29 (23–36) years and 128
(46.9%) patients were women. The median BMI was 20.8
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(18.7–22.4) kg/m2 and 5.7% were severely underweight.
HIV (5.8%) and diabetes (3.2%) were the most fre-
quently associated diseases. A total of 24.2% of the
patients were smokers, 34.6% were alcohol abusers, and
14.1% were illicit drug users. Table 1 shows the demo-
graphic and clinical data of TB patients with and without
ATDH development. Alcohol abuse was more frequent
in controls (P= 0.002). An increased risk of ATDH
development was linked to female sex (OR: 1.94; 95%
CI: 1.20–3.14; P= 0.006).
Table 2 describes the genotypic frequencies of seven
common NAT2 SNPs. All polymorphisms were in HW
equilibrium, except G191A, because of its uncommon
occurrence in these populations. Therefore, G191A was
not investigated further. We found that none of the six
NAT2 SNPs was associated with ATDH (data not shown)
and for the genotype distribution, we did not find a sig-
nificant deviation from HW equilibrium.
The slow acetylator profile was higher in patients who
developed hepatotoxicity (P< 0.001) (Table 3). We tes-
ted the inheritance model on the acetylator profile using
logistic regression. The best model fits when the slow
acetylator profile is used as a recessive variable, and rapid
and intermediate acetylator as only one variable (rapid
acetylator). A significant association was observed
between a slow acetylator profile and ATDH develop-
ment (OR: 2.93; 95% CI: 1.78–4.82; P< 0.001) (Table 3).
The c1/c1 genotype of the CYP2E1 gene was the most
frequent in our population and both groups studied.
Variants that contained the c2 allele (c1/c2 and c2/c2
genotypes) were more prevalent in patients who devel-
oped hepatotoxicity (P= 0.004). We tested the inheri-
tance model on the CYP2E1 C-1056T genotype using
logistic regression and the model fit using the c2 allele as
a dominant variable (c1/c2 and c2/c2 vs. c1/c1). Our results
indicated that the c2 allele was associated with ATDH
development (OR: 2.19; 95% CI: 1.32–3.48; P= 0.002).
The VNTR polymorphism of the CYP2E1 gene was
genotyped, and only four variants were found: A1/A2, A2/
A2 (or 1C/1C), A2/A4 (or 1C/1D), and A4/A4 (or 1D/1D).
Genotypes containing the A3 allele were not detected in
our population. Only one patient was a carrier of the A1
allele and this patient was not considered in further
analyses. The homozygous wild-type genotype (A2/A2)
was the most frequent in all the groups studied (>83%).
The A4 variant was poorly represented in our studied
population, but we found that patients who were carriers
of the A4 allele showed a trend for an increased risk of
ATDH (OR: 1.99; 95% CI: 1.00–3.96; P= 0.050)
(Table 3).
GSTM1 and GSTT1 genotyping showed an increased
frequency of the GSTM1 null genotype in our population
(46.7%), but the GSTT1 null genotype frequency was
lower and present in 19.1% of TB patients. Analyses of
the combined variant of GSTT1 and GSTM1 indicated
that only 7% of patients showed alterations of both GST
(null/null). These frequency distributions were main-
tained between the groups and no significant differences
were observed between the groups in individual or
combined GST genotypes (Table 3).
OR estimations related to genetic variables were adjusted
for sex, which was the only environmental variable
associated with an increased risk for ATDH development
to avoid environmental factors as potential confounders.
Slow acetylator profile and the CYP2E1 polymorphisms
c2 and A4 were independent predictors for ATDH.
Gene–gene and gene–environment interactions
The combined distributions of the acetylator profiles of
NAT2 with CYP2E1 c1/c2 genotypes were analyzed. An
increased risk was observed in patients who were slow
Table 1 Demographic and clinical characteristics of patients with
and without antituberculosis drug-induced hepatotoxicity
Variables
Without ATDH
(n=249)
With ATDH
(n=96) P
Age (years) 28 (23.0–36.8) 30 (23.3–35.8) 0.279
Sex (female) 32.1 (80) 47.9 (46) 0.006
BMI (kg/height2) 20.8 (18.8–22.2) 20.5 (18.4–23.4) 0.734
Severely
underweight
6.1 (15) 4.5 (4) 0.790
Associated
diseases
21.8 (54) 15.8 (15) 0.216
Smokers 26.1 (65) 18.8 (18) 0.152
Alcoholics 39.4 (98) 21.9 (21) 0.002
Drug abusers 16.1 (40) 8.3 (8) 0.063
Data are expressed as median with percentiles (25 and 75) or n (%).
ATDH, antituberculosis drug-induced hepatotoxicity.
Significant associations are indicated by bold text.
Table 2 Distribution of genotypic frequencies of N-acetyltransferase
2 variants in cases with antituberculosis drug-induced
hepatotoxicity and controls
Genotypes Without ATDH (n=247n) With ATDH (n=96) P
C282T 0.175
CC 40.1 (99) 38.5 (37)
CT 47 (116) 40.6 (39)
TT 12.9 (32) 20.8 (20)
T341C 0.971
TT 51.4 (127) 50 (48)
TC 39.3 (97) 40.6 (39)
CC 9.3 (23) 9.4 (9)
C481T 0.880
CC 51.8 (128) 50 (48)
CT 38.9 (96) 41.7 (40)
TT 9.3 (23) 8.3 (8)
G590A 0.392
GG 73.7 (182) 67.7 (65)
GA 25.5 (63) 30.2 (29)
AA 0.8 (2) 2.1 (2)
A803G 0.858
AA 49.8 (123) 46.9 (45)
AG 38.5 (95) 41.7 (40)
GG 11.7 (29) 11.5 (11)
G857A 0.152
GG 62.8 (155) 55.2 (53)
GA 30.8 (76) 32.3 (31)
AA 6.4 (16) 12.5 (12)
ATDH, antituberculosis drug-induced hepatotoxicity; NAT2, N-acetyltransferase 2.
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acetylators and carried the c2 allele of CYP2E1 (OR: 6.60;
95% CI: 3.14–13.86; P< 0.001) in ATDH prediction
(Table 4). After adjusting for sex, this increased risk
remained. Therefore, we used the MDR method to
improve our understanding of the gene–gene and
gene–environment interactions [32].
Table 5 presents the MDR analysis for each factor con-
sidered and summarizes the average CVC, average test-
ing balance accuracy (TBA) obtained, and the empirical
P-value derived from permutation testing. The best
model of gene–gene analysis that maximized TBA and
CVC was the two-factor model that included the geno-
typic variant of NAT2 and the genetics variants of
CYP2E1 (marked as SNP C-1053T and VNTR). This
model showed a maximum TBA of 0.653 (P= 0.001),
which indicates the ability to properly classify 65.3% of
the individuals included in the analysis, and a CVC of 10
out of 10 (10/10), which indicates that this particular
marker combination was chosen by MDR across the 10
runs. Gene–environmental interaction analyses that only
included the identified environmental risk factor (sex)
showed that the best model that maximized both para-
meters was the three-factor model [TBA= 0.675
(P= 0.001) and CVC= 10/10] that included sex in the
gene–gene model.
The interaction dendrogram (Fig. 1a) showed a strong
synergistic effect between the markers analyzed in
GSTT1 and in CYP2E1 genes associated with the risk for
ATDH. Sex and the NAT2 acetylator profile showed the
highest degree of redundancy in their interactions. We
also found that the sex/NAT2 cluster and the GSTT1/
CYP2E1 cluster showed a redundant interaction, but to a
lower degree. No interaction was found between GSTM1
and other variables. The interaction entropy graph indi-
cated that the NAT2 acetylator profile eliminated 4.88%
of entropy and the main large independent effect in
ATDH development, followed by CYP2E1 (2.15%) and
sex (1.54%). The synergistic interaction between GSTT1
and CYP2E1 genes removed a considerable percentage of
the entropy (1.44%) (Fig. 1b).
Discussion
To our knowledge, this report is the first study to eval-
uate environmental factors and polymorphisms in
enzymes that metabolize anti-TB drugs together and
investigate potential gene–gene and gene–environment
interactions and their association with ATDH develop-
ment in a population of hospitalized TB patients from
Buenos Aires. Our primary finding was a prediction
model that properly identified 67.5% of the TB patients
at risk of developing ATDH. We also showed for the first
time a synergistic effect between CYP2E1 and GSTT1,
which suggests a potential gene–gene interaction (epis-
tasis) associated with increased risk for ATDH.
Several environmental factors, including sex, age, BMI,
nutrition status, diseases in course, comedication, and
environmental agents, influence drug effects. We ana-
lyzed whether some of these influential variables were
Table 3 Genetic frequencies of cytochrome P450 2E1, glutathione S-transferases, and N-acetyltransferase 2 acetylator profile in cases with
antituberculosis drug-induced hepatotoxicity and controls
Total sample
(n=345)
Without ATDH
(n=249)
With ATDH
(n=96) P OR (95% CI) (P) OR adjusted by sex (95% CI) (P)
NAT2 phenotype
RA 12.8 (44) 12.5 (31) 13.5 (13) < 0.001 SA vs. others: 2.931 (1.783–4.819)
(P<0.001)
SA vs. others: 3.017 (1.822–4.996)
(P<0.001)
IA 38.8 (133) 46.2 (114) 19.8 (19)
SA 48.4(166) 41.3 (102) 66.7 (64)
CYP2E1
C-1053T
c1/c1 63.5 (219) 68.7 (171) 50 (48) 0.004 c2 carriers vs. c1/c1: 2.192
(1.355–3.548) (P=0.001)
c2 carriers vs. c1/c1: 2.156
(1.325–3.507) (P=0.002)
c1/c2 31.6 (109) 26.5 (66) 44.8 (43)
c2/c2 4.9 (17) 4.8 (12) 5.2 (5)
VNTR
A2/A2 88.7 (305) 90.8 (226) 83.2 (79) 0.047 A4 carriers vs. others: 1.990
(1.001–3.958) (P=0.050)
A4 carriers vs. others: 2.131
(1.059–4.290) (P=0.050)
A2/A4 11 (38) 8.8 (22) 16.8 (16)
A4/A4 0.3 (1) 0.4 (1) 0
GSTT1
Wild 80.9 (279) 80.7 (201) 81.3 (78) 0.911 – –
Null 19.1 (66) 19.3 (48) 18.8 (18)
GSTM1
Wild 53.3 (184) 54.2 (135) 51 (49) 0.596 – –
Null 46.7 (161) 45.8 (114) 49 (47)
GSTT1 and GSTM1
Wild/wild 41.2 (142) 42.2 (105) 38.5 (37) 0.741 – –
Wild/null 51.9 (179) 50.6 (126) 55.2 (53)
Null/null 7 (24) 7.2 (18) 6.3 (6)
ATDH, antituberculosis drug-induced hepatotoxicity; CI, confidence interval; CYP2E1, cytochrome P450 2E1; GSTM1, glutathione S-transferase mu 1; GST, glutathione
S-transferase; IA, intermediate acetylator; NAT2, N-acetyltransferase 2; OR, odds ratio; RA, rapid acetylator; SA, slow acetylator; VNTR, variable number tandem repeat.
Significant associations are indicated by bold text.
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associated with ATDH development in our TB popula-
tion and we found that female sex was an important risk
factor for ATDH. This result is consistent with pre-
viously reported findings that women are particularly
predisposed to ATDH [19,33]. Other clinical variables
studied that could affect our results (i.e. drug abuse,
alcohol abuse, etc.) were not observed to be predictive for
ATDH. Surprisingly, alcohol abuse was higher in the
control group than in the cases; therefore, this variable
was not taken into account for further analysis.
TB treatment involves a multidrug scheme, but some
reports indicate that alterations in the INH metabolic
pathway are primarily responsible for the occurrence of
ATDH. This hypothesis likely stemmed from the
ability of RMP to act as a potent inducer of CYP2E1
activity and as a reducer of NAT2 activity, which
increase the accumulation of Hz and toxic metabolites
[14,15]. PZA increases the hepatotoxicity of INH [34],
and nontoxic concentrations of INH and hydrazine
increase in-vitro PZA hepatotoxicity [35]. Several sur-
veys reported that genetic alterations in the enzymes
involved in the metabolic pathways of INH were
associated with hepatotoxicity [36–39]. We investigated
the pharmacogenetics of INH, and our results support
this hypothesis.
The CYP2E1 c1/c2 polymorphism and ATDH suscept-
ibility were studied widely in several populations [19,21,
23,40–42]. Several surveys found an association between
the c1/c1 (RsaI+ ) variant and the development of ATDH
[13,21], but other studies found no associations [19,41,42].
Notably, a significant association was observed between c2
allele carriers and the development of ATDH, which
suggests that this allele is an independent risk factor for
hepatotoxicity in our population (Table 3). Our results are
contradictory to some studies, but consistent with
Watanabe et al. [43], who suggested that the c2 variant
shows higher transcriptional activity, protein levels, and
enzyme activity than the wild-type variant (c1). Sharma
et al. [44] reported similar findings in a North Indian
population and proposed a re-examination of the previous
report adjusting for confounder factors. However, few
studies have examined whether VNTR polymorphisms of
the CYP2E1 gene were associated with ATDH suscept-
ibility [10,45,46]. We found that A4 carriers show an
increased risk of ATDH development (Table 3). This
result is consistent with previous studies that proposed
that the transcriptional activity of the A4 allele (containing
eight repetitive units, also named *1D) was higher than
the A2 allele (containing six repetitive units, also named
*1C) [47]. A higher transcriptional activity of CYP2E1
would promote the hepatotoxic pathway. To the best of
our knowledge, this study is the first report to identify an
association between the A4 allele and ATDH suscept-
ibility. It is possible that other groups did not find an
association because of the low number of ATDH patients
recruited to achieve statistical power [Santos et al. [46]Ta
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(n= 18) and Cho et al. [10] (n= 18)]. Kudryashov et al. [45]
found an association between the A2/A2 genotype with an
increase in serum alanine aminotransferase activity within
the normal range of values, but no hepatotoxicity criteria
were defined.
GSTM1 and GSTT1 null mutations are associated with
idiosyncratic DILI caused by a large variety of drugs [24]
and ATDH development [18,25]. Fukino et al. [36]
reported that the Hz concentration was higher in GSTM1-
null than wild-type patients. No individual or combined
association between GSTT1 null and GSTM1 null with
hepatotoxicity was found in our population (Table 3).
The lack of individual influence of GSTs in ATDH
development may be because these enzymes act down-
stream in the INH metabolic pathway and its action only
became important in the presence of a slow acetylator
profile or in c2 carriers. Another hypothesis is that other
detoxifying enzymes are involved in INH toxic meta-
bolites that scavenge the bypassing GSTT1 and GSTM1
pathway (Table 3).
Table 5 Multifactor dimensionality reduction: models detected and their performance
Number of markers considered Best candidate model CVCa TBAb P *
Gene–gene interaction
1 NAT2 10/10 0.614 0.008
2 NAT2, CYP2E1 (C-1053T+VNTR) 10/10 0.653 0.001
3 NAT2, CYP2E1 (C-1053T+VNTR), GSTT1 9/10 0.606 0.014
4 NAT2, CYP2E1 (C-1053T+VNTR), GSTM1, GSTT1 10/10 0.603 0.026
Gene–environment interaction (sex)
1 NAT2 10/10 0.614 0.020
2 NAT2, CYP2E1 (C-1053T+VNTR) 10/10 0.653 0.001
3 NAT2, CYP2E1 (C-1053T+VNTR), sex 10/10 0.675 0.001
4 NAT2, CYP2E1 (C-1053T+VNTR), sex, GSTT1 9/10 0.625 0.008
5 NAT2, CYP2E1 (C-1053T+VNTR), sex, GSTT1, GSTM1 10/10 0.613 0.020
The bold fonts indicate the overall best MDR model.
CVC, cross-validation consistency; CYP2E1, cytochrome P450 2E1; GSTM1, glutathione S-transferase mu 1; GSTT1, glutathione S-transferase theta 1;
MDR, multifactor dimensionality reduction; TBA, testing balanced accuracy; VNTR, variable-number tandem repeat.
aCVC: measure of how many times out of 10 divisions of the data, MDR found the same best model.
bTBA: measure of the predictive performance of the model, the one with the highest TBA represents the best overall model.
Number of markers considered.
*P-value based on 1000 permutations: shows the statistical significance of the model.
Fig. 1
(a) Interaction dendrogram for the markers tested in the multifactor dimensionality reduction (MDR) analysis to evaluate associations with
antituberculosis drug-induced hepatotoxicity (ATDH). The lines represent a continuum from synergy to redundancy of gene–gene and gene–sex
interactions with a variable strength. The color of the line indicates the type of interaction between factors. The red line suggests a high degree of
synergy. The gold line represents independence or additivity. The blue line suggests a high degree of redundancy or correlation, and the green line
indicates a lower degree of redundancy. (b) Entropy-based interaction circle graph for ATDH with MDR. Entropy values in the cells of particular factors
indicate the main independent effects and the entropy values on the lines connecting two factors represent the entropy of the interaction. The NAT2
phenotype removes 4.88% of entropy, which, in theory, means that this factor eliminates 4.88% of ‘uncertainty’ in the prediction of ATDH. VNTR and
c1/c2 polymorphism in CYP2E1 removes 2.15% of ‘uncertainty’. The environmental factor sex removes 1.54% of entropy. Interaction between
GSTT1 and CYP2E1 removes 1.44% entropy and this range of information is not explained by any of these factors treated separately (synergistic
interaction). ATDH, antituberculosis drug-induced hepatotoxicity; CYP2E1, cytochrome P450 2E1; GSTT1, glutathione S-transferase theta 1;
MDR, multifactor dimensionality reduction; NAT2, N-acetyltransferase 2; VNTR, variable-number tandem repeat.
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Analysis of the acetylator profile showed that ATDH
primarily developed in patients who were slow acet-
ylators (66.7%). The slow acetylator profile was an
independent variable that was associated with an
increased risk of developing ATDH (Table 3), which is
consistent with our previously reported data [19]. This
study examined the interaction of the acetylator profile
with other risk factors in the prediction of ATDH. The
combination of the c1/c2 with acetylator status analyses
showed that a defective NAT2 enzyme (slow acetylator)
and wild-type CYP2E1 (c1/c1) increased the risk of
ATDH. Our hypothesis is that the alternative metabolic
pathway prevails and INH is hydrolyzed directly to form
Hz. However, the risk of developing ATDH is aug-
mented when NAT2 is acetylated normally, but the c2
variant of CYP2E1 is present. This hypothesis may be
explained by the fact that the c2 variant shows higher
transcriptional activity, protein levels, and enzyme
activity than the wild-type variant. Therefore, CYP2E1
may oxidize more acetyl hydrazine to hepatotoxic inter-
mediates. Additive effects are observed when these
alterations occur simultaneously, with a higher risk of
hepatotoxicity than patients who show only a slow acet-
ylator profile or are c2 carriers (Table 4).
We analyzed gene–gene and gene–sex interactions to
gain a better understanding of ATDH mechanisms.
MDR analysis indicated that the NAT2 acetylator profile
was the highest individual risk factor for ATDH. The
best model for ATDH prediction from gene–gene
interaction was the interaction between NAT2 and
CYP2E1. This model supported the findings in Table 4.
However, the model fit better when a gene–sex inter-
action was analyzed. Therefore, inclusion of the sex
variable in the genotypic classification of CYP2E1 and
acetylator profile increased to the 67.5% the ability to
properly classify individuals in their risk to develop
ATDH.
The interaction entropy graph provides more detailed
information on the interaction of variables in the pre-
diction of ATDH. Contrary to our expectation and the
results of the logistic regression in Table 4, these results
suggest that the interaction between all markers con-
sidered in the best model provides redundant informa-
tion. This result means that each marker removes more
entropy on its own that the interactions between them.
However, a synergistic interaction was found between
GSTT1 and CYP2E1 genes, which indicates possible
epistasis between variants in these two genes in ATDH
cases, even when GSTT1 did not show an individual
association with the adverse effect. The presence of a
synergistic effect in the absence of main effects would fit
the classical definition of epistasis (Fig. 1b). One expla-
nation for this finding is that increased activity of
CYP2E1 in TB patients with a c1/c2 or c2/c2 genotype
leads to an augmented concentration of hepatotoxins that
cannot be scavenged by the GSTT1 pathway (in null
genotypes), which increases the risk of ATDH.
This study elucidated the interaction of different genetic
polymorphisms in enzymes involved in INH metabolism
with each other and female sex increased the risk of
ATDH. However, one limitation of our investigation was
the low number of cases, which should be higher to
achieve greater statistical power. The population of TB
patients analyzed received a four-drug treatment, and we
cannot obviate drugs interactions and their influence in
the hepatotoxicity explained above. Therefore, further
pharmacogenetics studies of the metabolic pathway of
PZA and RMP should be carried out to gain a better
understanding of ATDH mechanisms. Our study
achieved a very acceptable prediction model that may aid
early detection in patients with an increased risk
of ATDH.
ATDH is a severe, potentially fatal, and prevalent
adverse drug reaction, and it leads to drug discontinua-
tion in 11% of TB patients. Our study designed a pre-
diction model that adequately identified 67.5% of
patients with TB in their risk of developing ATDH. The
considerable number of TB patients in our country sup-
ports the fact that the use of early pharmacogenetic
testing and a comprehensive clinical history may be
useful in identifying patients with a high risk of suffering
hepatotoxicity. This type of research further supports the
use of personalized medicine in the treatment of TB and
might be further carried out on the new anti-TB
acrylamide-derived drugs [48] because the genotoxicity
of this vinyl monomer is known [49].
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